Sponsored by:

Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines

Will Morton, Associate Editor, AuntMinnie.com. Headshot
Will Morton
Jun 22, 2025

NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.

Latest in Molecular Imaging
Prostate Imaging
Novartis secures expanded approval for Pluvicto
July 31, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Money Pile 400
Ratio Therapeutics adds to coffers
July 31, 2026
Snmmi
SNMMI issues analysis of 2027 HOPPS proposed rule
July 29, 2026
Related Stories
Quality
Risk Management
SNMMI: For PET drugs, sterility assurance bests sterility testing
SNMMI President Jean-Luc Urbain, MD, PhD
Molecular Imaging
Urbain takes helm as SNMMI president
Ad
Molecular Imaging
Study highlights clinical potential of tau PET scans
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Molecular Imaging
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
PET/MRI detects arterial inflammation in prostate cancer patients
By Will Morton
Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer, yet is associated with increased cardiovascular events such as stroke and heart attacks.
July 31, 2026
Representative axial fused F-18 FDG-PET/MRI images and corresponding anatomic MRI images from a patient imaged at baseline and after initiation of androgen deprivation therapy are shown. Each row displays a distinct vascular territory. White arrows indicate focal areas of increased tracer uptake within the arterial wall, where spherical volumes of interest (VOIs) were placed for maximum standardized uptake value (SUVmax) measurement. Additional VOIs were placed in the superior vena cava and inferior vena cava for blood-pool activity sampling. SUVmax values from the arterial VOIs were extracted on the corresponding PET images and normalized to the blood-pool mean standardized uptake value to derive the maximum target-to-background ratio.
Ratio Therapeutics adds to coffers
By AuntMinnie.com staff writers
Both new and existing investors participated in the $70 million series C financing round.
July 31, 2026
Money Pile 400
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Vanderbilt Health, Siemens enter partnership valued at $87 million
By AuntMinnie.com staff writers
Siemens Healthineers will supply MRI, CT, molecular imaging, interventional radiology, and radiation oncology systems for Vanderbilt Health locations.
July 27, 2026
Acquisitions
Curium reintroduces Tl-201 in the U.S.
By AuntMinnie.com staff writers
Production of the radiopharmaceutical had ceased in 2022.
July 27, 2026
Nuclear Medicine
SPECT/CT viable over PET/CT for high-risk prostate cancer staging
By Will Morton
Considering its broader accessibility, Tc-99m MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging.
July 24, 2026
Maximum intensity projection of Ga-68 PSMA-11 PET/CE-CT (A), Tc-99m MIP-1404 CZT SPECT/CT (B) and Tc-99m HDP CZT SPECT/CT (C) imaging. Ga-68 PSMA-11 PET/CE-CT and Tc-99m MIP-1404 CZT SPECT/CT showing tracer uptake in lymph nodes below the iliac bifurcation and above, paraaortic and left supraclavicular, bone uptake in the right proximal femur and right scapula (arrows). Tc-99m HDP CZT SPECT/CT did not show any uptake suspicious for metastatic disease. No sclerotic lesions suspicious of metastases were detected by the CT component in any of the studies. Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (D) and Tc-99m MIP-1404 CZT SPECT/CT (E) showing uptake in lymph nodes in the left pelvic area below the iliac bifurcation (arrows). Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (F) and Tc-99m MIP-1404 CZT SPECT/CT (G) showing uptake in the right proximal femur, not detected by Tc-99m HDP CZT SPECT/CT (H), (arrows).
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo New March 2023
Spectrum Dynamics expands Veriton SPECT/CT line
By AuntMinnie.com staff writers
The company has unveiled an all-energy enhancement for its CT-400 series digital SPECT/CT scanner.
July 20, 2026
Veriton CT 400 Series digital SPECT/CT scanner with all-energy enhancement.
Tau PET tracer flags early Alzheimer risk in healthy older adults
By Will Morton
Few studies have investigated how F-18 PI-2620 is associated with memory performance or AD-related biomarkers in cognitively unimpaired older adults.
July 17, 2026
F-18 PI-2620 average binding potential maps. Mean tracer binding (DVR) image from 165 older adults (A) and 13 young adults (B). Images are scaled from 1 to 1.8 for display purposes, but DVR values of less than 1 were frequently observed.
Page 1 of 632
Next Page